Nanjing Vazyme Biotech Co., Ltd (SHA:688105)

Market Cap	9.14B
Revenue (ttm)	1.36B
Net Income (ttm)	-21.40M
Shares Out	397.73M
EPS (ttm)	-0.07
PE Ratio	n/a
Forward PE	95.75
Dividend	0.30 (1.32%)
Ex-Dividend Date	Jun 5, 2025

Volume	4,100,457
Average Volume	1,819,749
Open	22.89
Previous Close	22.98
Day's Range	21.99 - 22.97
52-Week Range	16.85 - 29.69
Beta	0.96
RSI	55.10
Earnings Date	Aug 29, 2025

About Nanjing Vazyme Biotech

Nanjing Vazyme Biotech Co., Ltd offers technology solutions for life science, biomedicine, and in vitro diagnostics. The company offers reagents for molecular biology research, such as nucleic acid extraction, PCR, cloning/mutagenesis, nucleic acid electrophoresis, reverse transcription, real-time PCR (qPCR), genome editing, and cell biology/protein research; reagents for NGS library preparation, including automated liquid handling workstation, DNA sequencing, RNA sequencing, single cell-seq series, epigenetics series, beads series, quantificat...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 2,867
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688105

Financial Performance

In 2024, Nanjing Vazyme Biotech's revenue was 1.38 billion, an increase of 7.15% compared to the previous year's 1.29 billion. Losses were -18.09 million, -74.50% less than in 2023.